The Korean journal of internal medicine

  • 제32권3호
  • /
  • Pages.478-485
  • /
  • 2017
  • /
  • 1226-3303(pISSN)
  • /
  • 2005-6648(eISSN)
대한내과학회 (The Korean Association of Internal Medicine)
권호 표지
DOI QR코드

DOI QR Code

Clinical significance of positive Pneumocystis jirovecii polymerase chain reaction in non-human immunodeficiency virus immunocompromised patients in a real practice

  • Lee, Hea Yon (Division of Pulmonary Medicine, Department of Internal Medicine, The Catholic University of Korea) ;
  • Kang, Hye Seon (Division of Pulmonary Medicine, Department of Internal Medicine, The Catholic University of Korea) ;
  • Lee, Hwa Young (Division of Pulmonary Medicine, Department of Internal Medicine, The Catholic University of Korea) ;
  • Rhee, Chin Kook (Division of Pulmonary Medicine, Department of Internal Medicine, The Catholic University of Korea) ;
  • Lee, Sook Young (Division of Pulmonary Medicine, Department of Internal Medicine, The Catholic University of Korea) ;
  • Kim, Seok Chan (Division of Pulmonary Medicine, Department of Internal Medicine, The Catholic University of Korea) ;
  • Kim, Seung Joon (Division of Pulmonary Medicine, Department of Internal Medicine, The Catholic University of Korea) ;
  • Park, Yeon Joon (Department of Laboratory Medicine, College of Medicine, The Catholic University of Korea) ;
  • Kim, Young Kyoon (Division of Pulmonary Medicine, Department of Internal Medicine, The Catholic University of Korea) ;
  • Kang, Ji Young (Division of Pulmonary Medicine, Department of Internal Medicine, The Catholic University of Korea)
  • 투고 : 2015.10.14
  • 심사 : 2016.04.04
  • 발행 : 2017.05.01
⟨ 이전 논문 다음 논문 ⟩

초록

Background/Aims: Pneumocystis jirovecii polymerase chain reaction (PCR) can be helpful in diagnosing Pneumocystis pneumonia (PCP); however it has limitations. We evaluated the prevalence of positive P. jirovecii PCR from non-human immunodeficiency virus (HIV) immunocompromised patients and tried to determine the risk of PCP development. Methods: Between May 2009 and September 2012, P. jirovecii PCR was performed in bronchoscopic specimens from 1,231 adult non-HIV immunocompromised patients suspected of respiratory infection. Only 169 patients (13.7%) who were tested positive for P. jirovecii PCR were enrolled. Retrospective chart review was performed. PCP was defined in patients with positive P. jirovecii PCR who were treated for PCP based on the clinical decision. Results: From 169 P. jirovecii PCR-positive patients, 90 patients were in the PCP group (53.3%) and 79 patients were in the non-PCP group (46.7%). In the PCP group, 38% of patients expired or aggravated after therapy, whereas the majority of patients (84%) in the non-PCP group recovered without treatment for PCP. Independent risk factors for PCP by binary logistic regression analysis were underlying conditions- hematological malignancies, solid tumors or solid organ transplantation, dyspnea, age < 60 years, and albumin < 2.9 g/dL. Conclusions: This study suggests that not all P. jirovecii PCR-positive patients need to be treated for PCP. Among P. jirovecii PCR-positive patients, those who are less than 60 years old, with hematological malignancies, solid tumors or solid organ transplantation, low albumin, and with symptoms of dyspnea, the possibility of PCP might be higher. Treatment should also be selected to these patients.

키워드

참고문헌

  1. Thomas CF Jr, Limper AH. Pneumocystis pneumonia. N Engl J Med 2004;350:2487-2498. https://doi.org/10.1056/NEJMra032588
  2. Overgaard UM, Helweg-Larsen J. Pneumocystis jiroveci pneumonia (PCP) in HIV-1-negative patients: a retrospective study 2002-2004. Scand J Infect Dis 2007;39:589-595. https://doi.org/10.1080/00365540601150497
  3. Roblot F, Godet C, Le Moal G, et al. Analysis of underlying diseases and prognosis factors associated with Pneumocystis carinii pneumonia in immunocompromised HIV-negative patients. Eur J Clin Microbiol Infect Dis 2002;21:523-531. https://doi.org/10.1007/s10096-002-0758-5
  4. Reid AB, Chen SC, Worth LJ. Pneumocystis jirovecii pneumonia in non-HIV-infected patients: new risks and diagnostic tools. Curr Opin Infect Dis 2011;24:534-544. https://doi.org/10.1097/QCO.0b013e32834cac17
  5. Morris A, Wei K, Afshar K, Huang L. Epidemiology and clinical significance of pneumocystis colonization. J Infect Dis 2008;197:10-17. https://doi.org/10.1086/523814
  6. Leibovitz E, Pollack H, Moore T, et al. Comparison of PCR and standard cytological staining for detection of Pneumocystis carinii from respiratory specimens from patients with or at high risk for infection by human immunodeficiency virus. J Clin Microbiol 1995;33:3004-3007.
  7. Lipschik GY, Gill VJ, Lundgren JD, et al. Improved diagnosis of Pneumocystis carinii infection by polymerase chain reaction on induced sputum and blood. Lancet 1992;340:203-206. https://doi.org/10.1016/0140-6736(92)90469-J
  8. Mekinian A, Durand-Joly I, Hatron PY, et al. Pneumocystis jirovecii colonization in patients with systemic autoimmune diseases: prevalence, risk factors of colonization and outcome. Rheumatology (Oxford) 2011;50:569-577. https://doi.org/10.1093/rheumatology/keq314
  9. Wakefield AE, Pixley FJ, Banerji S, et al. Detection of Pneumocystis carinii with DNA amplification. Lancet 1990;336:451-453. https://doi.org/10.1016/0140-6736(90)92008-6
  10. Kovacs JA, Masur H. Evolving health effects of Pneumocystis: one hundred years of progress in diagnosis and treatment. JAMA 2009;301:2578-2585. https://doi.org/10.1001/jama.2009.880
  11. The National Institutes of Health-University of California Expert Panel for Corticosteroids as Adjunctive Therapy for Pneumocystis Pneumonia. Consensus statement on the use of corticosteroids as adjunctive therapy for pneumocystis pneumonia in the acquired immunodeficiency syndrome. N Engl J Med 1990;323:1500-1504. https://doi.org/10.1056/NEJM199011223232131
  12. ARDS Definition Task Force, Ranieri VM, Rubenfeld GD, et al. Acute respiratory distress syndrome: the Berlin Definition. JAMA 2012;307:2526-2533.
  13. Levy MM, Fink MP, Marshall JC, et al. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med 2003;31:1250-1256. https://doi.org/10.1097/01.CCM.0000050454.01978.3B
  14. Marshall JC, Cook DJ, Christou NV, Bernard GR, Sprung CL, Sibbald WJ. Multiple organ dysfunction score: a reliable descriptor of a complex clinical outcome. Crit Care Med 1995;23:1638-1652. https://doi.org/10.1097/00003246-199510000-00007
  15. Fishman GI, Chugh SS, Dimarco JP, et al. Sudden cardiac death prediction and prevention: report from a National Heart, Lung, and Blood Institute and Heart Rhythm Society Workshop. Circulation 2010;122:2335-2348. https://doi.org/10.1161/CIRCULATIONAHA.110.976092
  16. Miller RF, Ambrose HE, Wakefield AE. Pneumocystis carinii f. sp. hominis DNA in immunocompetent health care workers in contact with patients with P. carinii pneumonia. J Clin Microbiol 2001;39:3877-3882. https://doi.org/10.1128/JCM.39.11.3877-3882.2001
  17. Tsolaki AG, Beckers P, Wakefield AE. Pre-AIDS era isolates of Pneumocystis carinii f. sp. hominis: high genotype similarity with contemporary isolates. J Clin Microbiol 1998;36:90-93.
  18. Tasaka S, Tokuda H. Pneumocystis jirovecii pneumonia in non-HIV-infected patients in the era of novel immunosuppressive therapies. J Infect Chemother 2012;18:793-806. https://doi.org/10.1007/s10156-012-0453-0
  19. Nevez G, Jounieaux V, Linas MD, et al. High frequency of Pneumocystis carinii sp.f. hominis colonization in HIV-negative patients. J Eukaryot Microbiol 1997;44:36S. https://doi.org/10.1111/j.1550-7408.1997.tb05760.x
  20. Chabe M, Dei-Cas E, Creusy C, et al. Immunocompetent hosts as a reservoir of pneumocystis organisms: histological and rt-PCR data demonstrate active replication. Eur J Clin Microbiol Infect Dis 2004;23:89-97. https://doi.org/10.1007/s10096-003-1092-2
  21. Morris A, Norris KA. Colonization by Pneumocystis jirovecii and its role in disease. Clin Microbiol Rev 2012;25:297-317. https://doi.org/10.1128/CMR.00013-12
  22. Torres HA, Chemaly RF, Storey R, et al. Influence of type of cancer and hematopoietic stem cell transplantation on clinical presentation of Pneumocystis jiroveci pneumonia in cancer patients. Eur J Clin Microbiol Infect Dis 2006;25:382-388. https://doi.org/10.1007/s10096-006-0149-4
  23. Fritzsche C, Riebold D, Munk-Hartig A, Klammt S, Neeck G, Reisinger E. High prevalence of Pneumocystis jirovecii colonization among patients with autoimmune inflammatory diseases and corticosteroid therapy. Scand J Rheumatol 2012;41:208-213. https://doi.org/10.3109/03009742.2011.630328
  24. Mori S, Cho I, Ichiyasu H, Sugimoto M. Asymptomatic carriage of Pneumocystis jiroveci in elderly patients with rheumatoid arthritis in Japan: a possible association between colonization and development of Pneumocystis jiroveci pneumonia during low-dose MTX therapy. Mod Rheumatol 2008;18:240-246. https://doi.org/10.3109/s10165-008-0037-0
  25. Kovacs JA, Hiemenz JW, Macher AM, et al. Pneumocystis carinii pneumonia: a comparison between patients with the acquired immunodeficiency syndrome and patients with other immunodeficiencies. Ann Intern Med 1984;100:663-671. https://doi.org/10.7326/0003-4819-100-5-663
  26. White DA, Wong PW, Downey R. The utility of open lung biopsy in patients with hematologic malignancies. Am J Respir Crit Care Med 2000;161(3 Pt 1):723-729. https://doi.org/10.1164/ajrccm.161.3.9904016
  27. Fujisawa T, Suda T, Matsuda H, et al. Real-time PCR is more specific than conventional PCR for induced sputum diagnosis of Pneumocystis pneumonia in immunocompromised patients without HIV infection. Respirology 2009;14:203-209. https://doi.org/10.1111/j.1440-1843.2008.01457.x
  28. Muhlethaler K, Bogli-Stuber K, Wasmer S, et al. Quantitative PCR to diagnose Pneumocystis pneumonia in immunocompromised non-HIV patients. Eur Respir J 2012;39:971-978. https://doi.org/10.1183/09031936.00095811
  29. Matsumura Y, Ito Y, Iinuma Y, et al. Quantitative real-time PCR and the (1$\rightarrow$3)-$\beta$-D-glucan assay for differentiation between Pneumocystis jirovecii pneumonia and colonization. Clin Microbiol Infect 2012;18:591-597. https://doi.org/10.1111/j.1469-0691.2011.03605.x
  30. Tasaka S, Kobayashi S, Yagi K, et al. Serum (1 $\rightarrow$ 3) $\beta$-D-glucan assay for discrimination between Pneumocystis jirovecii pneumonia and colonization. J Infect Chemother 2014;20:678-681. https://doi.org/10.1016/j.jiac.2014.07.001

피인용 문헌

  1. Infectious complications after hematopoietic stem cell transplantation: current status and future perspectives in Korea vol.33, pp.2, 2017, https://doi.org/10.3904/kjim.2018.036
  2. Epidemiology and clinical impact of viral, atypical, and fungal respiratory pathogens in symptomatic immunocompromised patients: a two-center study using a multi-parameter customized respiratory Taqma vol.38, pp.8, 2017, https://doi.org/10.1007/s10096-019-03579-y
  3. Albumin Neutralizes Hydrophobic Toxins and Modulates Candida albicans Pathogenicity vol.12, pp.3, 2017, https://doi.org/10.1128/mbio.00531-21